Innate immunity and inflammation in ageing: a key for understanding age-related diseases

Immunity & Ageing

Calogero Caruso¹  Claudio Franceschi²  Giuseppina Colonna-Romano¹  Elisa Porcellini³  Domenico Lio¹  Giuseppina Candore¹  Federico Licastro³ 

[1] Gruppo di Studio sull'Immunosenescenza, Dipartimento di Biopatologia e Metodologie Biomediche, Università di Palermo, Italy;Centro Interdipartimentale "L. Galvani", Università di Bologna, Bologna, Italy;Dipartimento di Patologia Sperimentale, Università di Bologna, Italy

关键词: Longevity;    Innate Immunity;    Inflammation;    Cytokine;    Age-related diseases;   

Others  :  819721
DOI  :  10.1186/1742-4933-2-8

 received in 2005-04-05, accepted in 2005-05-18,  发布年份 2005

【 摘 要 】

The process of maintaining life for the individual is a constant struggle to preserve his/her integrity. This can come at a price when immunity is involved, namely systemic inflammation. Inflammation is not per se a negative phenomenon: it is the response of the immune system to the invasion of viruses or bacteria and other pathogens. During evolution the human organism was set to live 40 or 50 years; today, however, the immune system must remain active for much a longer time. This very long activity leads to a chronic inflammation that slowly but inexorably damages one or several organs: this is a typical phenomenon linked to ageing and it is considered the major risk factor for age-related chronic diseases. Alzheimer's disease, atherosclerosis, diabetes and even sarcopenia and cancer, just to mention a few – have an important inflammatory component, though disease progression seems also dependent on the genetic background of individuals. Emerging evidence suggests that pro-inflammatory genotypes are related to unsuccessful ageing, and, reciprocally, controlling inflammatory status may allow a better chance of successful ageing. In other words, age-related diseases are "the price we pay" for a life-long active immune system: this system has also the potential to harm us later, as its fine tuning becomes compromised. Our immune system has evolved to control pathogens, so pro-inflammatory responses are likely to be evolutionarily programmed to resist fatal infections with pathogens aggressively. Thus, inflammatory genotypes are an important and necessary part of the normal host responses to pathogens in early life, but the overproduction of inflammatory molecules might also cause immune-related inflammatory diseases and eventually death later. Therefore, low responder genotypes involved in regulation of innate defence mechanisms, might better control inflammatory responses and age-related disease development, resulting in an increased chance of long life survival in a "permissive" environment with reduced pathogen load, medical care and increased quality of life.

【 授权许可】

   
2005 Licastro et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Medzhitov R, Janeway C Jr: Innate immunity. N Engl J Med 2000, 343:338-344.
• [2]Janeway C Jr, Medzhitov R: Viral interference with IL-1 and toll signaling. Annu Rev Immunol 2002, 20:197-216.
• [3]Krieger M: The other side of scavenger receptors: pattern recognition for host defense. Curr Opin Lipidol 1997, 8:275-280.
• [4]Muzio M, Natoli G, Saccani S, Levrero M, Mantovani A: The human toll signaling pathway: divergence of nuclear factor kappaB and JNK/SAPK activation upstream of tumor necrosis factor receptor-associated factor 6 (TRAF6). J Exp Med 1998, 187:2097-2101.
• [5]Guha M, Mackman N: LPS induction of gene expression in human monocytes. Cell Signal 2001, 13:85-94.
• [6]Mitchell RN, Cotran RS: Acute and Chronic Inflammation. In Robbins Basic Pathology. Saunderrs, Philadelphia, USA; 2003.
• [7]Lio D, Caruso C: IL-10, Genetic Polymorphism and Its Relevance to Age-related Diseases. In Interleukin-10 Edited by Francesco M Marincola. © 2004 Eurekah.com
• [8]Bidwell J, Keen L, Gallagher G, Kimberly R, Huizinga T, McDermott MF, Oksenberg J, McNicholl J, Pociot F, Hardt C, D'Alfonso S: Cytokine gene polymorphism in human disease: on-line databases. Genes Immun 1999, 1:3-19.
• [9]Gabay C, Kushner I: Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999, 340:448-54.
• [10]Pepys MB, Hirschfield GM: C-reactive protein: a critical update. J Clin Invest 2003, 111:1805-12.
• [11]Candore G, Colonna-Romano G, Lio D, Caruso C: Immunological and Immunogenetic markers of successful and unsuccessful ageing. Advances in Cell Aging and Gerontology 2003, 13:29-45.
• [12]Pawelec G, Ouyang Q, Colonna-Romano G, Candore G, Lio D, Caruso C: Is human immunosenescence clinically relevant? Looking for 'immunological risk phenotypes'. Trends Immunol 2002, 23:330-2.
• [13]Pawelec G, Akbar A, Caruso C, Effros R, Grübeck-Loebenstein B, Wikby A: Is immunosenescence infectious? Contribution of persistent Herpes viruses to immunosenescence and influence on human longevity. Trends Immunol 2004, 25:406-10.
• [14]Lloberas J, Celada A: Effect of aging on macrophage function. Exp Geront 2002, 37:1325-1331.
• [15]Renshaw M, Rockwell J, Engleman C, Gewirtz A, Katz J, Sambhara S: Cutting edge: impaired Toll-like receptor expression and function in aging. J Immunol 2002, 169:4697-4701.
• [16]Pawelec G, Solana R, Remarque E, Mariani E: Impact of aging on innate immunity. J Leukoc Biol 1998, 64:703-712.
• [17]Plackett TP, Boehmer ED, Faunce DE, Kovacs EJ: Aging and innate immune cells. J Lekoc Biol 2004, 76:1-9.
• [18]Di Lorenzo G, Balistreri CR, Candore G, Cigna D, Colombo A, Romano GC, Colucci AT, Gervasi F, Listi F, Potestio M, Caruso C: Granulocyte and natural killer activity in the elderly. Mech Ageing Dev 1999, 108:25-38.
• [19]Fagiolo U, Cossarizza A, Scala E, Fanales-Belasio E, Ortolani C, Cozzi E, Monti D, Franceschi C, Paganelli R: Increased cytokine production in mononuclear cells of healthy elderly people. Eur J Immunol 1993, 23:2375-2378.
• [20]Bruunsgaard H, Pedersen M, Pedersen BK: Aging and proinflammatory cytokines. Curr Opin Hematol 2001, 131:131-136.
• [21]Ershler WB, Keller ET: Age-associated increased interleukin-6 gene expression, late-life diseases, and frailty. Annu Rev Med 2000, 51:245-270.
• [22]Baggio G, Donazzan S, Monti D, Mari D, Martini S, Gabelli C, Dalla Vestra M, Previato L, Guido M, Pigozzo S, Cortella I, Crepaldi G, Franceschi C: Lipoprotein(a) and lipoprotein profile in healthy centenarians: a reappraisal of vascular risk factors. FASEB J 1998, 12:433-437.
• [23]Dumont P, Balbeur L, Remacle J, Toussaint O: Appearance of biomarkers of in vitro ageing after successive stimulation of WI-38 fibroblasts with IL-1alpha and TNF-alpha: senescence associated beta-galactosidase activity and morphotype transition. J Anat 2000, 197:529-537.
• [24]Vasto S, Caruso C: Immunity & Ageing: a new journal looking at ageing from an immunological point of view. Immun Ageing 2005, 2:1. BioMed Central Full Text
• [25]Pawelec G, Barnett Y, Forsey R, Frasca D, Globerson A, McLeod J, Caruso C, Franceschi C, Fulop T, Gupta S, Mariani E, Mocchegiani E, Solana R: T cells and aging. Front Biosci 2002, 7:d1056-1183.
• [26]Franceschi C, Bonafe M, Valensin S, Olivieri F, De Luca M, Ottaviani E, De Benedictis G: Inflamm-aging. An evolutionary perspective on immunosenescence. Ann N Y Acad Sci 2000, 908:208-218.
• [27]Franceschi C, Bonafe M: Centenarians as a model for healthy aging. Biochem Soc Trans 2003, 31:457-461.
• [28]Krabbe KS, Pedersen M, Bruunsgaard H: Inflammatory mediators in the elderly. Exp Gerontol 2004, 39:687-699.
• [29]Rudin E, Barzilai N: Inflammatory peptides derived from adipose tissue. Immun Ageing 2005, 2:1. BioMed Central Full Text
• [30]Finch CE, Crimmins EM: Inflammatory exposure and historical changes in human life-spans. Science 2004, 305:1736-1739.
• [31]Ridker PM, Morrow DA: C-reactive protein, inflammation, and coronary risk. Cardiol Clin 2003, 21:315-325.
• [32]Zhu J, Quyyumi AA, Norman JE, Csako G, Waclawiw MA, Shearer GM, Epstein SE: Effects of total pathogen burden on coronary artery disease risk and C-reactive protein levels. Am J Cardiol 2000, 85:140-146.
• [33]Ferrucci L, Harris TB, Guralnik JM, Tracy RP, Corti MC, Cohen HJ, Penninx B, Pahor M, Wallace R, Havlik RJ: Serum IL-6 level and the development of disability in older persons. J Am Geriatr Soc 1999, 47:639-646.
• [34]Harris TB, Ferrucci L, Tracy RP, Corti MC, Wacholder S, Ettinger WH Jr, Heimovitz H, Cohen HJ, Wallace R: Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med 1999, 106:506-512.
• [35]Volpato S, Guralnik JM, Ferrucci L, Balfour J, Chaves P, Fried LP, Harris TB: Cardiovascular disease, interleukin-6, and risk of mortality in older women: the women's health and aging study. Circulation 2001, 103:947-953.
• [36]Bruunsgaard H, Andersen-Ranberg K, Hjelmborg JB, Pedersen BK, Jeune B: Elevated levels of tumor necrosis factor alpha and mortality in centenarians. Am J Med 2003, 115:278-283.
• [37]Bruunsgaard H, Ladelund S, Pedersen AN, Schroll M, Jørgensen T, Pedersen BK: Predicting death from tumor necrosis factor-alpha and interleukin-6 in 80-year-old people. Clin Exp Immunol 2003, 132:24-31.
• [38]Reuben DB, Cheh AI, Harris TB, Ferrucci L, Rowe JW, Tracy RP, Seeman TE: Peripheral blood markers of inflammation predict mortality and functional decline in high-functioning community-dwelling older persons. J Am Geriatr Soc 2002, 50:638-644.
• [39]Mysliwska J, Bryl E, Foerster J, Mysliwski : A. Increase of interleukin 6 and decrease of interleukin 2 production during the ageing process are influenced by the health status. Mech Ageing Dev 1998, 100:313-328.
• [40]Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, Seeman T, Tracy R, Kop WJ, Burke G, McBurnie MA: Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001, 56:M146-M156.
• [41]Hamerman D: Toward an understanding of frailty. Ann Intern Med 1999, 130:945-950.
• [42]Roubenoff R, Hughes V: Sarcopenia: current concepts. J Gerontol A Biol Sci Med Sci 2000, 55:M716-M724.
• [43]Brown W: A method for estimating the number of motor units in thenar muscles and the changes in motor unit count with aging. J Neurosurg Psych 1972, 35:845-852.
• [44]Roubenoff R: Catabolism of aging: is it an inflammatory process? Curr Opin Clin Nutr Metab Care 2003, 6:295-299.
• [45]Pedersen M, Bruunsgaard H, Weis N, Hendel HW, Andreassen BU, Eldrup E, Dela F, Pedersen BK: Circulating levels of TNF-alpha and IL-6-relation to truncal fat mass and muscle mass in healthy elderly individuals and in patients with type-2 diabetes. Mech Ageing Dev 2003, 124:495-502.
• [46]Visser M, Pahor M, Taaffe DR, Goodpaster BH, Simonsick EM, Newman AB, Nevitt M, Harris TB: Relationship of interleukin-6 and tumor necrosis factor-alpha with muscle mass and muscle strength in elderly men and women: the Health ABC study. J Gerontol A Biol Sci Med Sci 2002, 57:M326-M332.
• [47]Ferrucci L, Penninx BW, Volpato S, Harris TB, Bandeen-Roche K, Balfour J, Leveille SG, Fried LP, Md JM: Change in muscle strength explains accelerated decline of physical function in older women with high interleukin-6 serum levels. J Am Geriatr Soc 2002, 50:1947-1954.
• [48]Greiwe JS, Cheng B, Rubin DC, Yarasheski KE, Semenkovich CF: Resistance exercise decreases skeletal muscle tumor necrosis factor alpha in frail elderly humans. FASEB J 2001, 15:475-482.
• [49]Bruunsgaard H, Bjerregaard E, Schroll M, Pedersen BK: Muscle strength following resistance training is inversely correlated with baseline levels of soluble tumor necrosis Factor receptors in the oldest old. J Am Geriatr Soc 2004, 52:237-241.
• [50]Barbieri M, Ferrucci L, Ragno E, Corsi A, Bandinelli S, Bonafe M, Olivieri F, Giovagnetti S, Franceschi C, Guralnik JM, Paolisso G: Chronic inflammation and the effect of IGF-I on muscle strength and power in older persons. Am J Physiol Endocrinol Metab 2003, 284:E481-487.
• [51]Cappola AR, Xue QL, Ferrucci L, Guralnik JM, Volpato S, Fried LP: Insulin-like growth factor I and interleukin-6 contribute synergistically to disability and mortality in older women. J Clin Endocrinol Metab 2003, 88:2019-2025.
• [52]Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G: Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 2001, 280:E745-E751.
• [53]Senn J, Klover P, Nowak I, Mooney R: Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes 2002, 51:3391-3399.
• [54]Hotamisligil GS, Shargill NS, Spiegelman BM: Adipose expression of tumor necrosis factor-alpha: direct role in obesity linked insulin resistance. Science 1993, 259:87-91.
• [55]Kereiakes DJ, Willerson JT: Metabolic syndrome epidemic. Circulation 2003, 108:1552-1553.
• [56]Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Heath CW Jr: Body-mass index and mortality in a prospective cohort of U.S. adults. N Engl J Med 1999, 341:1097-105.
• [57]Neel JV: Diabetes mellitus: a "thrifty" genotype rendered detrimental by "progress"? Am J Hum Genet 1962, 14:353-362.
• [58]Diamond J: The double puzzle of diabetes. Nature 2003, 423:599-602.
• [59]Lazar MA: How obesity causes diabetes: not a tall tale. Science 2005, 307:373-375.
• [60]Tracy RO: Inflammation, the metabolic syndrome and cardiovascular risk. Int Clin Pract Suppl 2003, 134:10-17.
• [61]Das U: Metabolic syndrome X: an inflammatory condition? Curr Hypertens Rep 2004, 6:66-73.
• [62]Kern PA, Saghizadeh M, Ong JM, Bosch RJ, Deem R, Simsolo RB: The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest 1995, 95:2111-2119.
• [63]Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW: C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 1999, 19:972-978.
• [64]Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS, Klein S, Coppack SW: Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-α, in vivo. J Clin Endocrinol Metab 1997, 82:4196-4200.
• [65]Lundgren CH, Brown SL, Nordt TK, Sobel BE, Fujii S: Elaboration of type-1 plasminogen activator inhibitor from adipocytes. A potential pathogenetic link between obesity and cardiovascular disease. Circulation 1996, 93:106-110.
• [66]Curat CA, Miranville A, Sengenes C, Diehl M, Tonus C, Busse R, Bouloumie A: From blood monocytes to adipose tissue-resident macrophages: induction of diapedesis by human mature adipocytes. Diabetes 2004, 53:1285-1292.
• [67]Perseghin G, Petersen K, Shulman GI: Cellular mechanism of insulin resistance: potential links with inflammation. Int J Obes Relat Metab Disord 2003, 3:s6-11.
• [68]Haffner SM: Insulin resistance, inflammation, and the prediabetic state. Am J Cardiol 2003, 92:18J-26J.
• [69]Dandona P, Aljada A, Bandyopadhyay A: Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol 2004, 25:4-7.
• [70]Spranger J, Kroke A, Mohlig M, Hoffmann K, Bergmann MM, Ristow M, Boeing H, Pfeiffer AF: Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes 2003, 52:812-817.
• [71]Festa A, Hanley AJ, Tracy RP, D'Agostino R Jr, Haffner SM: Inflammation in the prediabetic state is related to increased insulin resistance rather than decreased insulin secretion. Circulation 2003, 108:1822-1830.
• [72]Temelkova-Kurktschiev T, Siegert G, Bergmann S, Henkel E, Koehler C, Jaross W, Hanefeld M: Subclinical inflammation is strongly related to insulin resistance but not to impaired insulin secretion in a high risk population for diabetes. Metabolism 2002, 51:743-749.
• [73]Abbatecola AM, Ferrucci L, Grella R, Bandinelli S, Bonafe M, Barbieri M, Corsi AM, Lauretani F, Franceschi C, Paolisso G: Diverse effect of inflammatory markers on insulin resistance and insulin-resistance syndrome in the elderly. J Am Geriatr Soc 2004, 52:399-404.
• [74]Hotamisligil GS, Budavari A, Murray D, Spiegelman BM: Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes. Central role of tumor necrosis factor-α. J Clin Invest 1994, 94:1543-1549.
• [75]Kubaszek A, Pihlajamaki J, Komarovski V, Lindi V, Lindstrom J, Eriksson J, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Tuomilehto J, Uusitupa M, Laakso M: Finnish Diabetes Prevention Study. Promoter polymorphisms of the TNF-alpha (G-308A) and IL-6 (C-174G) genes predict the conversion from impaired glucose tolerance to type 2 diabetes: the Finnish Diabetes Prevention Study. Diabetes 2003, 52:1872-1876.
• [76]Aljada A, Ghanim H, Mohanty P, Kapur N, Dandona P: Insulin inhibits the pro-inflammatory transcription factor early growth response gene-1 (Egr)-1 expression in mononuclear cells (MNC) and reduces plasma tissue factor (TF) and plasminogen activator inhibitor-1 (PAI-1) concentrations. J Clin Endocrinol Metab 2002, 87:1419-1422.
• [77]Das M, Gabriely I, Barzilai N: Caloric restriction, body fat and ageing in experimental models. Obes Rev 2004, 5:13-19.
• [78]De Pinho RA: The age of cancer. Nature 2000, 408:248-254.
• [79]Caruso C, Lio D, Cavallone L, Franceschi C: Aging, Longevity, Inflammation, and Cancer. Ann NY Acad Sci 2004, 1028:1-13.
• [80]Repetto L, Venturino A, Fratino L, Serraino D, Troisi G, Gianni W, Pietropaolo M: Geriatric oncology: a clinical approach to the older patient with cancer. Eur J Cancer 2003, 39:870-880.
• [81]Thun MJ, Henley SJ, Gansler T: Inflammation and cancer: an epidemiological perspective. Novartis Found Synp 2004, 256:2-21.
• [82]Macarthur M, Hold GL, El-Omar EM: Inflammation and Cancer II. Role of chronic inflammation and cytokine gene polymorphisms in the pathogenesis of gastrointestinal malignancy. Am J Physiol Gastointest Liver Physiol 2004, 286:G515-20.
• [83]Brigati C, Noonan DM, Albini A, Benelli R: Tumors and inflammatory infiltrates: friends or foes? Clin Exp Metastasis 2002, 19:247-258.
• [84]Balkwill F, Mantovani A: Inflammation and cancer: back to Virchow. Lancet 2001, 357:539-545.
• [85]Erlinger TP, Platz EA, Rifai N, Helzlsouer KJ: C-reactive protein and the risk of incident colorectal cancer. JAMA 2004, 291:585-90.
• [86]McMillan DC, Canna K, McArdle CS: Systemic inflammatory response predicts survival following curative resection of colorectal cancer. Br J Surg 2003, 90:215-219.
• [87]Bonafe M, Olivieri F, Cavallone L, Giovagnetti S, Mayegiani F, Cardelli M, Pieri C, Marra M, Antonicelli R, Lisa R, Rizzo MR, Paolisso G, Monti D, Franceschi C: A gender – dependent genetic predisposition to produce high levels of IL-6 is detrimental for longevity. Eur J Immunol 2001, 31:2357-2361.
• [88]Lio D, Scola L, Crivello A, Colonna-Romano G, Candore G, Bonafe M, Cavallone L, Franceschi C, Caruso C: Gender-specific association between -1082 IL-10 promoter polymorphism and longevity. Genes Immun 2002, 3:30-33.
• [89]Lio D, Scola L, Crivello A, Colonna-Romano G, Candore G, Bonafe M, Cavallone L, Marchegiani F, Olivieri F, Franceschi C, Caruso C: Inflammation, genetics, and longevity: further studies on the protective effects in men of IL-10 -1082 promoter SNP and its interaction with TNF-alpha -308 promoter SNP. J Med Genet 2003, 40:296-299.
• [90]Caruso C, Candore G, Colonna Romano G, Lio D, Bonafe M, Valensin S, Franceschi C: HLA, aging, and longevity: a critical reappraisal. Hum Immunol 2000, 61:942-249.
• [91]Shin HD, Park BL, Kim LH, Jung JH, Kim JY, Yoon JH, Kim YJ, Lee HS: Interleukin 10 haplotype associated with increased risk of hepatocellular carcinoma. Hum Mol Genet 2003, 12:901-906.
• [92]Hussain SP, Hofseth LJ, Harris CC: Radical causes of cancer. Nature Rev Cancer 2003, 3:276-285.
• [93]Szlosarek PW, Balkwill FR: Tumor necrosis factor alpha: a potential target for the therapy of solid tumors. Lancet Oncol 2003, 4:565-573.
• [94]Braunwald E: Shattuck lecture – cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. N Engl J Med 1997, 337:1360-1369.
• [95]Libby P, Ridker PM, Maseri A: Inflammation and atherosclerosis. Circulation 2002, 105:1135-1143.
• [96]Ross R: Atherosclerosis: An inflammatory disease. N Engl J Med 1999, 340:115-126.
• [97]Lusis AJ: Atherosclerosis. Nature 2000, 407:233-241.
• [98]Libby P: Inflammation in atherosclerosis. Nature 2002, 420:868-874.
• [99]Rifai N, Ridker PM: Proposed cardiovascular risk assessment algorithm using high-sensitivity C-reactive protein and lipid screening. Clin Chem 2001, 47:28-30.
• [100]Ridker PM, Rifai N, Stampfer MJ, Hennekens CH: Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000, 101:1767-1772.
• [101]Hansson GK, Libby P, Schonbeck U, Yan ZQ: Innate and aquired immunity in the pathogenesis of atherosclerosis. Circulation Res 2002, 91:281-291.
• [102]Ridker PM, Hennekens CH, Buring JE, Rifai N: C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000, 342:836-843.
• [103]Ridker PM, Rifai N, Rose L, Buring JE, Cook NR: Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002, 347:1557-1565.
• [104]Di Iorio A, Ferrucci L, Sparvieri E, Cherubini A, Volpato S, Corsi A, Bonafe M, Franceschi C, Abate G, Paganelli R: Serum IL-1beta levels in health and disease: a population-based study. 'The InCHIANTI study'. Cytokine 2003, 22:198-205.
• [105]Barbieri M, Ferrucci L, Corsi AM, Macchi C, Lauretani F, Bonafe M, Olivieri F, Giovagnetti S, Franceschi C, Paolisso G: Is chronic inflammation a determinant of blood pressure in the elderly? Am J Hypertens 2003, 16:537-543.
• [106]Nabel EG: Cardiovascular disease. N Engl J Med 2003, 349:60-72.
• [107]Andreotti F, Porto I, Crea F, Maseri A: Inflammatory gene polymorphisms and ischaemic heart disease: review of population association studies. Heart 2002, 87:107-112.
• [108]Stephens JW, Humphries SE: The molecular genetics of cardiovascular disease: clinical implications. J Intern Med 2003, 253:120-127.
• [109]Lio D, Candore G, Crivello A, Scola L, Colonna-Romano L, Cavallone L, Hoffmann E, Caruso M, Licastro F, Caldarera CM, Branzi A, Franceschi C, Caruso C: Opposite effects of IL-10 gene polymorphisms in cardiovascular diseases and in successful ageing: genetic background of male centenarians is prospettive against coronary heart disease. J Med Genet 2004, 41:790-794.
• [110]Listì F, Candore G, Lio D, Cavallone L, Colonna-Romano G, Caruso M, Hoffmann E, Caruso C: Association between platelet endothelial cellular adhesion molecule 1 (PECAM-1/CD31) polymorphisms and acute myocardial infarction: a study in patients from Sicily. Eur J Immunogenet 2004, 31:175-178.
• [111]Licastro F, Chiappelli M, Caldarera CM, Tampieri C, Nanni S, Gallina M, Branzi A: The concomitant presence of polymorphic alleles of interleukin-1beta, interleukin-6 and apolipoprotein E is associated with an increased risk of myocardial infarction in elderly men. Results from a pilot study. Mech Ageing Dev 2004, 125:575-579.
• [112]Benagiano M, Azzurri A, Ciervo A, Amedei A, Tamburini C, Ferrari M, Telford JL, Baldari CT, Romagnani S, Cassone A, D'Elios MM, Del Prete G: T helper type 1 lymphocytes drive inflammation in human atherosclerotic lesions. Proc Natl Acad Sci U S A. Epub 2003, 100:6658-6663.
• [113]Gupta S, Pablo AM, Jiang X, Wang N, Tall AR, Schindler C: IFN-gamma potentiates atherosclerosis in ApoE knock-out mice. J Clin Invest 1997, 99:2752-2761.
• [114]Whitman SC, Ravisankar P, Elam H, Daugherty A: Exogenous interferon-gamma enhances atherosclerosis in apolipoprotein E-/- mice. Am J Pathol 2000, 157:1819-1824.
• [115]Hansson GK: The B cell: a good guy in vascular disease? Arterioscler Thromb Vasc Biol 2002, 22:523-524.
• [116]Wick G, Knoflach M, Xu Q: Autoimmune and inflammatory mechanisms in atherosclerosis. Annu Rev Immunol 2004, 22:361-403.
• [117]Brookmeyer R, Gray S, Kawas C: Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health 1998, 88:1337-1342.
• [118]Selkoe DJ: Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 2001, 81:741-766.
• [119]Ritchie K, Lovestone S: The dementias. Lancet 2002, 360:1759-1766.
• [120]McGeer EG, McGeer PL: The importance of inflammatory mechanisms in Alzheimer disease. Exp Geront 1998, 33:371-378.
• [121]Licastro F: Genomics of immune molecules: early detection of cognitive decline and new therapeutic interventions. Expert Rev Neurotherapeutics 2002, 2:639-645.
• [122]Lee YB, Nagai A, Kim SU: Cytokines, chemokines, and cytokine receptors in human microglia. J Neurosci Res 2002, 69:94-103.
• [123]In t' Veld BA, Ruitenberg A, Hofman A: Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J Med 2001, 345:1515-1521.
• [124]Vagnucci AH Jr, Li WW: Alzheimer's disease and angiogenesis. Lancet 2003, 361:605-608.
• [125]Schmidt R, Schmidt H, Curb JD, Masaki K, White LR, Launer LJ: Early inflammation and dementia: a 25-year follow-up of the Honolulu-Asia Aging Study. Ann Neurol 2002, 52:168-174.
• [126]Licastro F, Pedrini S, Caputo L, Annoni G, Davis LJ, Ferri C, Casadei V, Grimaldi LM: Increased plasma levels of interleukin-1, interleukin-6 and alpha-1-antichymotrypsin in patients with Alzheimer's disease: peripheral inflammation or signals from the brain? J Neuroimmunol 2000, 103:97-102.
• [127]Licastro F, Pedrini S, Ferri C, Casadei V, Govoni M, Pession A, Sciacca FL, Veglia F, Annoni G, Bonafe M, Olivieri F, Franceschi C, Grimaldi LM: Gene polymorphism affecting alpha1-antichymotrypsin and interleukin-1 plasma levels increases Alzheimer's disease risk. Ann Neurol 2000, 48:388-391.
• [128]De Luigi A, Fragiacomo C, Lucca U, Quadri P, Tettamanti M, Grazia De Simoni M: Inflammatory markers in Alzheimer's disease and multi-infarct dementia. Mech Ageing Dev 2001, 122:1985-1995.
• [129]Licastro F, Chiappelli M: Brain immune responses cognitive decline and dementia: relationship with phenotype expression and genetic background. Mech Ageing Dev 2003, 124:525-528.
• [130]Licastro F, Grimaldi LM, Bonafe M, Martina C, Olivieri F, Cavallone L, Giovanietti S, Masliah E, Franceschi C: Interleukin-6 gene alleles affect the risk of Alzheimer's disease and levels of the cytokine in blood and brain. Neurobiol Aging 2003, 24:921-926.
• [131]Candore G, Balistreri CR, Colonna-Romano G, Lio D, Caruso C: Major histocompatibility complex and sporadic Alzheimer's disease: a critical reappraisal. Exp Gerontol 2004, 39:645-52.
• [132]Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, Finch CE, Frautschy S, Griffin WS, Hampel H, Hull M, Landreth G, Lue L, Mrak R, Mackenzie IR, McGeer PL, O'Banion MK, Pachter J, Pasinetti G, Plata-Salaman C, Rogers J, Rydel R, Shen Y, Streit W, Strohmeyer R, Tooyoma I, Van Muiswinkel FL, Veerhuis R, Walker D, Webster S, Wegrzyniak B, Wenk G, Wyss-Coray T: Inflammation and Alzheimer's disease. Neurobiol Aging 2000, 21:383-421.
• [133]Scola L, Licastro F, Chiappelli M, Franceschi C, Grimaldi LM, Crivello A, Colonna-Romano G, Candore G, Lio D, Caruso C: Allele frequencies of +874T – > A single nucleotide polymorphism at the first intron of IFN-gamma gene in Alzheimer's disease patients. Aging Clin Exp Res 2003, 15:292-295.
• [134]Lio D, Licastro F, Scola L, Chiappelli M, Grimaldi LM, Crivello A, Colonna-Romano G, Candore G, Franceschi C, Caruso C: Interleukin-10 promoter polymorphism in sporadic Alzheimer's disease. Genes Immun 2003, 4:234-238.
• [135]McGeer PL, McGeer EG: Polymorphisms in inflammatory genes and the risk of Alzheimer disease. Arch Neurol 2001, 58:1790-1792.
• [136]Nesse RM, Williams GC: Evolution and Healing. The New Science of Darwinian Medicine. Weidenfeld & Nicolson, UK; 1995.
• [137]Brod SA: Unregulated inflammation shortens human functional longevity. Inflamm Res 2000, 49:561-570.
• [138]Franceschi C, Olivieri F, Marchegiani F, Cardelli M, Cavallone L, Capri M, Salvioli S, Valensin S, De Benedictis G, Di Iorio A, Caruso C, Paolisso G, Monti D: Genes involved in immune response/inflammation, IGF1/insulin pathway and response to oxidative stress play a major role in the genetics of human longevity: the lesson of centenarians. Mech Ageing Dev 2005, 126:351-361.
• [139]Caruso C, Candore G, Colonna-Romano G, Lio D, Franceschi C: Inflammation and life-span. Science 2005, 307:208-209.
• [140]Wick G, Berger P, Jansen-Durr P, Grubeck-Loebenstein B: A Darwinian-evolutionary concept of age-related diseases. Exp Gerontol 2003, 38:13-25.
• [141]Mariani L, Turchetti G, Franceschi C: Chronic antigenic stress, immunosenescence and human survivorship over the 3 last centuries: heuristic value of a mathematical model. Mech Ageing Dev 2003, 124:453-458.
• [142]Balistreri CR, Candore G, Colonna-Romano G, Lio D, Caruso M, Hoffmann E, Franceschi C, Caruso C: Role of Toll-like receptor 4 in acute myocardial infarction and longevity. JAMA 2004, 292:2339-2340.